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Abstract 
White spot syndrome virus (WSSV) is a highly virulent shrimp pathogen, causing huge 
economic loss to the aquaculture industry. We investigated the efficacy of recombinant 
VP39 protein against WSSV infection in Litopenaeus vannamei by intramuscular and oral 
administration, and also compared the efficacy with recombinant VP28 (rVP28). The VP39 
is a 283 amino acid protein encoded by the structural gene vp39 which acts as an 
important mediator for virus entry to the host. Shrimp orally vaccinated with rVP39 and 
rVP28 showed a cumulative mortality of 50% and 60% respectively following challenge, 
and this indicates that rVP39 had a better protective effect against WSSV infection 
compared with rVP28. Vaccination by intramuscular injection with rVP39 and rVP28 resulted 
in survival rate of 60% and 50%, respectively. The transcriptional profiling of viral genes of 
vaccinated shrimp with recombinant viral proteins of VP28 showed higher transcriptional 
levels than VP39. The transcriptional level of rVP39 vaccinated animals was delayed by 6 
days after WSSV infection, while the delay was only 4 days in the case of rVP28. These 
results indicate that vaccination delays the transcription of envelope genes of WSSV in 
shrimp. The present study could demonstrate the importance of VP39 as a prominent 
candidate for vaccination against WSSV. 
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Introduction 
White spot syndrome virus (WSSV) is a rapidly replicating and highly virulent shrimp 
pathogen, which can cause up to 100% mortality within 7 to 10 days in shrimp farms, 
resulting in huge economic losses to the aquaculture industry (Witteveldt et al., 2004a). 
The virus has a broad host range which comprises shrimps, prawns, lobsters, copepods, 
crabs, and other arthropods (Lo et al., 1996; Maeda et al., 1998; Shi et al., 2000; 
Chakraborty et al., 2002). The infection is characterized by clinical signs such as lethargy, 
anorexia, loose cuticle from underlying epidermis, and the appearance of white spots on 
the inner side of the carapace, appendages, and the abdominal segments (Lightner, 1996; 
Hameed et al., 1998; Wang et al., 1999; Escobedo-Bonilla et al., 2007). WSSV belongs to 
the unique genus called Whispovirus in the family Nimaviridae, reported in the 8th Report 
of the International Committee on Taxonomy of Viruses (ICTV) (Vlak et al., 2005). It is a 
large, oval, enveloped DNA virus, with tail-like appendages at one end (Wongteerasupaya 
et al., 1995; Chang et al., 1996; Durand et al., 1997; Nadala et al., 1998). The size of the 
virion particles ranges between approximately 210-420 nm in length and 70-167 nm in 
diameter (Guoxing et al., 1997; Lotz and Soto, 2002). The viral nucleocapsid contains   
circular double stranded DNA with an approximate size of 300 kbp, with 181 non-
overlapping open reading frames consisting of 39 structural proteins (van Hulten et al., 
2001 and Yang et al., 2001).  
An adaptive immune system based on clonal expansion of activated lymphocytes, as 
found in vertebrates, is not present in shrimp and hence it is thought that they rely mostly 
on innate immune response for internal defense against parasites and pathogens (Söderhäll 
and Thornqvist, 1997). However in vivo experiments with Penaeus japonicus infected with 
WSSV revealed the presence of a quasi-immune response when the shrimp were re-
challenged with WSSV (Venegas et al., 2000). This suggests that there is some sort of 
adaptive immune response in shrimp (Kurtz and Franz, 2003; Kurtz, 2005). A short 
memory of antigen in shrimp might involve an induced secretion of neutralizing substances 
or other defense proteins against WSSV invasion (Granof and Webster, 1999) and this 
could be used to protect these animals against the disease.  
 Development of a vaccine based on the envelope proteins of WSSV could be more 
effective since they are the first molecules to interact with the host. Among the structural 
proteins, VP28 has been reported to be the most abundant and exposed protein of WSSV 
which facilitates the entry of the virion into the host cell at the early stage of infection (van 
Hulten et al., 2001). Several studies have shown that a recombinant vaccine based on 
VP28 provides notable protective effect against WSSV infection and has proven to be the 
best and most promising vaccine (Namikoshi et al., 2004; Witteveldt et al., 2004a, b; Jha 
et al., 2006; Du et al., 2006). Another structural gene, 852 bp long VP39, encodes a 283 
amino acid protein with a calculated molecular mass of 32 kDa which seems to be an 
important mediator for virus entry into the host (Zhu et al., 2006), and has been identified 
as an integument protein (Tsai et al., 2006). Temporal analysis of VP39 gene expression 
has shown that it is expressed 12 h after viral infection, and immunoelectron microscopy 
suggests that this is an envelope protein, but western blot analysis indicated its presence in 
both virions and viral envelopes (Zhu et al., 2006). VP39 has been identified as an 
integument protein (Tsai et al. 2006). However, the role of this protein in the infectivity of 
WSSV, or its interaction with shrimp receptors facilitating virus attachment and invasion, 
remains to be elucidated. There have been no reports in the literature regarding the 
efficiency of VP39 in inducing protection. Therefore, we investigated the efficacy of 
recombinant VP39 expressed in E. coli and delivered through intramuscular and oral 
administration, against WSSV infection in Pacific white shrimp, Litopenaeus vannamei. 
    
Materials and Methods 
Collection and maintenance of shrimp. Shrimp (L. vannamei) approximately 7-10 g body 
weight, were collected from a shrimp farm located in Kundapura, Karnataka and kept in 
1000 liter fiberglass tanks containing sand filtered and ozone treated natural seawater 
[salinity between 15-20 parts per thousand (ppt)], with vigorous aeration at 28-30°C. The 
shrimp were fed with artificial feed pellets and were acclimatized in the tanks for a week 
prior to the experiment. The shrimp were randomly screened for WSSV, IHHNV, MBV and 
HPV by polymerase chain reaction (PCR). Only healthy shrimp were used in the 
experiments. 
 Protection of L. vannamei against WSSV using VP39 and VP28 3 
 
 Preparation of WSSV inoculum. The viral inoculum was prepared from the gills of WSSV 
infected shrimp according to the method described by Xie et al. (2005) with minor 
modifications. The infected tissues were homogenized in TNE buffer (50mM Tris-Cl, 400mM 
NaCl, 5mM EDTA; pH 8.5) with protease inhibitors and centrifuged, filtered through nylon 
net and again centrifuged for 30 min at 4°C. The pellets were suspended in 10 ml TN buffer 
(50mM Tris-HCl, 10mM MgCl2, pH 7.5), and centrifuged for 20 min at 4°C followed by re-
suspension in 10 ml TN buffer containing 0.1% NaN3 and stored at -80°C. 50 µl of viral 
filtrate was used for the challenge study. The WSSV copy number was determined by 
quantitative real-time PCR (data not shown). 
 Bacterial expression of VP39 and VP28 proteins. The complete VP28 and VP39 open 
reading frame (ORF) was amplified from the genome of WSSV using primer VP28 F (5’-
CCGGGATCCATGGATCTTTCTTTCACTCTTTC-3’), VP28 R (5’-CGCAAGCTTCTCGGTCTCAGTGCCAG-3’)  
and VP39 F (5’-CGCAAGCTTATGTCGTCTAACGGAGATGA-3’) and VP39 R (5’-
CGGGATCCAAAAACAAACAGATTG-3’) with BamHI and EcoRI restriction enzyme sites 
(underlined). PCR was carried out under the following conditions: 95°C for 5 min, 30 cycles 
of denaturation at 95°C for 1 min, annealing at 60°C (VP28) and 50°C (VP39) for 1 min, 
extension step at 72°C for 1 min and final extension of 72°C for 10 min. The products of 
vp28 and vp39 genes were cloned into pET-32a (+) expression vector and transformed into 
E. coli BL21 (DE3) (pSBET A). To determine the expression of recombinant proteins, E. coli 
BL21 (DE3) (pSBET A) harboring recombinant plasmid pET-32a-VP28 and pET-32a-VP39 
were cultured in Luria-Bertani (LB) broth (HiMedia) containing 100 mg/ml ampicillin, 50 
mg/ml kanamycin, and incubated at 37°C to exponential phase with constant agitation at 
150 rpm. Expressions of recombinant proteins were then induced with 1mM IPTG 
(isopropyl-1-1-thio-b-d-galactoside) for 4 h. Expressed VP28 and VP39 proteins were 
purified by Ni-NTA affinity chromatography and purity of these proteins were analyzed by 
SDS-PAGE and specificity of the proteins were confirmed by western blotting (Towbin et al., 
1979). The purified recombinant proteins were used for vaccination experiments.  
 Subunit vaccination with rVP28 and rVP39 proteins. L. vannamei weighing 
approximately 7-10g were divided into 5 groups in triplicate (n=10 in each) and all shrimp 
in these groups were intramuscularly (IM) injected with 100 µl purified recombinant 
proteins rVP28, rVP39, mixture of both (rVP28+rVP39), and two groups were injected using 
a 29 gauge needle, with phosphate buffered saline (PBS) in the 4th or 5th tail segment as 
positive and negative control. The dose of recombinant proteins injected was 10 µg/g per 
shrimp. Ten days after the first dose, shrimp were immunized with a booster dose of the 
same concentration of the recombinant proteins. On the 20th day post initial vaccination 
(dpv), shrimp were challenged intramuscularly with a known concentration of WSSV (2.4 × 
104 copies) and were then monitored daily until 10 days post challenge. The dead shrimp 
were analyzed for the presence of WSSV by PCR. Hemolymph was collected from the 
cephalothorax of moribund shrimp using a 3-ml syringe with 23G needle. The hemolymph 
and organs were stored at -80°C until RNA extraction. 
 Oral vaccination experiment. The recombinant proteins over-expressed in E. coli BL21 
(DE3) (pSBET A) cells were inactivated with 0.5% formaldehyde and incubated for 15 min 
at 20°C followed by mixing with the feed pellets (approximately 107 cells). They were then 
incubated on ice for 15 min to facilitate absorption of the bacterial suspension and coated 
with cod liver oil to prevent dispersion of the inactivated bacteria in the water (Witteveldt 
et al., 2004b). The prepared feed pellets were used for oral vaccination by feeding three 
times daily at the rate of 3.5% of shrimp body weight. The shrimp were divided into six 
groups (10 per group) and vaccinated as shown in Table 1 for 7 consecutive days. Seven 
days after final vaccination, the shrimp in 5 groups were challenged by injecting WSSV (2.4 
× 104 copies). The 6th group received only PBS injection (negative control). Shrimp were 
monitored daily and the dead shrimp were analyzed for WSSV infection by PCR. 
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Table 1. Experimental set up for oral vaccination. 
     Total RNA extraction and cDNA 
synthesis. Total RNA was 
extracted from the hemolymph of 
WSSV challenged shrimp by using 
TRI reagent (Sigma-Aldrich) 
according to the manufacturer’s 
instructions. Complementary DNA 
(cDNA) was prepared from 1 μg of 
each RNA sample in a 20 µl 
reaction volume by using reverse 
transcriptase (Fermentas, UAB, Lithuania) and gene specific reverse primer; reaction was 
carried out at 42°C for 60 min. The expression levels of VP39 and VP28 genes were 
determined by PCR by using cDNA as template. Shrimp β-actin gene was used as internal 
control by using primers Actin F (5- GTGACTCACTTTGTCCCCGT- 3’), Actin R (5- 
TTACGCTCAGGAGGAGCAAT- 3’). The PCR products obtained were analyzed on agarose gel 
electrophoresis. 
 Statistical analysis. The protection conferred by the recombinant coat proteins against 
WSSV infection in shrimp was statistically represented as relative percentage survival 
(RPS). It was calculated as RPS = [1 – (mortality in vaccinated group / mortality in control 
group)] × 100 (Amend, 1981). 
 
Results 
Cloning and expression of VP28 and VP39 proteins. The complete ORF of both VP28 and 
VP39 genes were amplified from the viral DNA, and products were of expected length of 
615 and 852 bp, respectively (Fig.1).  
 
 
 
 The amplified products were purified and cloned into pET-32a (+) expression vector 
followed by expression in E. coli BL21 (DE3) (pSBET A). The size of recombinant protein 
was about 40.12 kDa and 49.72 kDa including His-tag corresponding to VP28 and VP39 
proteins respectively, by SDS-PAGE analysis. This was further confirmed by western blot 
analysis using polyclonal antibodies (Fig.2 A and B). 
 
 
 
 
 
SI 
No. 
Groups      No.of  
shrimps/group 
1 VP 28 10 × 3 
2 VP 39 10 × 3 
3 Recombinant E. coli BL21 (DE3) (pSBET 
A) cells with empty pET-32a (+) vector 
10 × 3 
4 Non-recombinant E. coli BL21 (DE3) 
(pSBET A) cells 
10 × 3 
5 Positive Control 10 × 3 
6 Negative Control 10 × 3 
Fig. 1. Agarose gel 
electrophoresis showing 
PCR amplification of WSSV 
envelope genes. Lane M: 
100 bp molecular weight 
marker; Lane 1: VP28 gene 
(615 bp); Lane 2: VP39 
gene  (852 bp); Lane 3: 
Negative control. 
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Subunit vaccination with envelope proteins (rVP28 and rVP39). The cumulative mortality of 
the vaccinated shrimp following challenge with WSSV was 50%, 40% and 40% with rVP28, 
rVP39 and rVP39+rVP28, respectively (Fig.3).  
 
 
 
 
 
 
 
 
 
 
 
 
The cumulative mortality for these vaccinated groups was significantly lower than that of 
the control group. RPS values of rVP39 and rVP28 groups were found to be 60 and 50, 
respectively. Highest survival rate was in the group vaccinated with rVP39. All the dead 
shrimp tested positive for WSSV infection by PCR. 
 In vivo expression of vp28 and vp39 gene in intramuscularly injected shrimps. The RT-
PCR of the transcripts from hemolymh of vaccinated shrimp challenged with WSSV showed 
a variation in the quantity of mRNA transcriptional level (Fig.4 and 5).  
 
 
 
 
Fig. 4. RT-PCR analysis of viral gene transcription in 
vaccinated shrimp with recombinant envelope protein VP28. 
Lane M: 100 bp Molecular weight DNA marker; Lane 1:  1 day 
after post initial vaccination; Lanes 2-6:  2nd, 4th, 6th, 8th and 
10th day of post initial vaccination. 
 
 
 
 
 
 
 
Fig. 2a. SDS–PAGE showing the expression of 
recombinant protein VP28 of WSSV.  
Lane M: Molecular weight marker (PMW-M); Lane 1: 
Non-recombinant BL21 (DE3) (pSBET A) E. coli, cell 
without IPTG induction; Lane 2: Non-recombinant 
BL21 (DE3) (pSBET A) E. coli, cell with IPTG 
induction; Lane 3: Recombinant VP28 clone without 
IPTG; Lanes 4-6: Recombinant VP28 clones with 
IPTG; Lane 7: Purified VP28 protein; Lane 8: 
Western blot analysis of purified VP28 protein by 
using polyclonal antibody. 
 
Fig. 2b. SDS–PAGE showing the expression of 
recombinant protein VP39 of WSSV.  
Lane M: Molecular weight marker (PMW-M); Lane 1: 
Non-recombinant BL21 (DE3) (pSBET A) E. coli, cell 
without IPTG induction; Lane 2: Non-recombinant 
BL21 (DE3) (pSBET A) E. coli, cell with IPTG 
induction; Lane 3: Recombinant VP39 clone without 
IPTG; Lanes 4-6: Recombinant VP39 clones with 
IPTG; Lane 7: Purified VP39 protein; Lane 8: Western 
blot analysis of purified VP39 protein by using 
polyclonal antibodies. 
 
 
Fig. 3. Cumulative mortality 
of L. vannamei vaccinated 
with recombinant envelope 
protein VP28 and VP39 by 
injection method. 
 
Fig. 5.   RT-PCR analysis of viral gene transcription in 
vaccinated shrimp with recombinant envelope protein VP39. 
Lane M: 100 bp Molecular weight DNA marker; Lane 1: 1 
day after post initial vaccination; Lanes 2-6:  2nd, 4th, 6th, 
8th and 10th day of post initial vaccination. 
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Expression level of mRNA of β-actin from the host was similar in every sample and even it 
is included as an internal control for checking the quality of RNA (Fig.6).  
 
 
 
 
 
 
 
 
 
The transcriptional pattern of viral genes in the hemolymph of shrimp vaccinated with 
recombinant viral proteins VP28 showed higher transcriptional levels compared with the 
batch vaccinated with VP39 protein. In the case of the latter, the transcription level was 
delayed by 6 days, while the delay was 2 days in the case of shrimp vaccinated with VP28. 
These transcriptome results have clearly indicated that the vaccination of shrimp, delays 
the transcription of envelope and tegument genes of WSSV following challenge. 
 Oral vaccination. A comparison was made between the efficacy of orally administered 
bacterially expressed proteins rVP39 protein and rVP28. The cumulative mortality results 
from the experiment are shown in Fig.7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups of shrimp vaccinated with rVP39 or rVP28 resulted in cumulative mortality of 50% 
and 60%, respectively, 10 days after viral challenge whereas positive control and group fed 
with E. coli BL21 cells containing empty vector resulted in 100% mortality at 10 dpi. 
Protective efficacy of rVP39 was higher compared to rVP28. The PCR analysis indicated that 
all the dead shrimp were infected with WSSV. There was no mortality in the negative 
control until the end of experimental period. 
 
Discussion 
In this study, we determined the efficacy of bacterially expressed recombinant envelope 
proteins VP28 and VP39, against WSSV infection by oral and intramuscular administration 
in Pacific white shrimp, L. vannamei. The envelope proteins are targeted mainly for 
vaccination studies because these proteins are the first to interact with the host defense 
system and stimulate protective immune response. These envelope proteins may play 
major roles in entry, assembly, and budding of viruses in the host (Chiu and Chang, 2002; 
Chazal and Gerlier, 2003). There have been number of reports regarding the role of VP28 
as an effective vaccine candidate for providing long term protection against WSSV in 
shrimp (Witteveldt et al., 2004a; Jha et al., 2006; Satoh et al., 2008). Literature did not 
yield any information about the immunization trials using VP39. We have attempted to 
develop a VP39 based vaccine and compared its protective efficacy with VP28.  
This study demonstrates that in L. vannamei vaccination by recombinant WSSV proteins 
VP28 and VP39 increased survival rate compared to the control groups. Oral vaccination of 
shrimp with rVP39 or rVP28 resulted in significantly lower mortality than that among the 
control shrimp. Vaccination with VP39 produced a lower cumulative mortality rate of 50% 
compared to VP28 (60%) and control groups (100%) 10 days post infection.  
 
 
Fig.6. RT-PCR analysis of internal control β-actin 
gene. Lanes 1-6: 1st, 2nd, 4th, 6th, 8th and 10th day of 
post initial vaccination. 
 
Fig. 7. Cumulative mortality of L. 
vannamei vaccinated orally with 
recombinant envelope protein VP28 
and VP39. 
 
 Protection of L. vannamei against WSSV using VP39 and VP28 7 
 
 The duration and extent of protection provided by VP28 vaccine varies in different 
studies with different shrimp species. The term ‘immunization’ though used by several 
researchers in shrimp, is not a true vaccination as in vertebrates. It is a quasi immune 
response that suggests the existence of adaptive immunity. WSSV is a serious pathogen of 
shrimp and is known to cause 100% mortality in 3-10 days. Delaying mortality even by a 
few days is considered very significant. The difference in the number of days between the 
control and the treated groups of shrimp when 100% mortality was recorded suggests the 
usefulness of the molecules in delaying mortality by a quasi-immune response. It was 
reported that the oral administration of feed pellets coated with inactivated bacteria 
expressing envelope protein VP28 could confer 61% protection to P. monodon against 
WSSV, but at the same time rVP19 failed to give any protection to the same (Wittaveldt et 
al., 2004b). A double dose of rVP28 could confer protection to P. japonicus with a survival 
rate of 95% 30 days post vaccination (Namikoshi et al., 2004) whereas a cumulative 
mortality of 41.7% was shown by rVP28 vaccinated L. vannamei 21 days after viral 
challenging (Choi et al., 2011). The oral administration of P. monodon with baculovirus 
expressed VP28 showed survival rates of 81.7% and 76.7% on 3 and 15 days post 
immunization (Syed Musthaq and Kwang, 2011). In Mar supenaeus japonicus, the oral 
vaccination of rVP28 could give 100% protection 30 days after viral challenging whereas 
the immunization by immersion and injection could provide only 70% and 30% protection, 
respectively (Satoh et al., 2008). According to Satoh et al, the high survival rate after oral 
vaccination might be due to the prevention of horizontal transmission of WSSV through 
cannibalism in shrimp farms. The over expression of VP28 in silkworm pupae with 
recombinant baculovirus in Procambarus clarkii could effectively inhibit WSSV by 
supplementing as oral feed (Wei and Xu, 2009). Recombinant VP28 expressed in Pichia 
pastoris showed 78% survival of P. clarkii 21 days after virus challenge (Jha et al., 2006). 
P. japonicus  treated with oral supplementation of feed pellets containing rVP28 expressed 
in gram positive bacteria exhibited high survival rates from WSSV, and the protection was 
dose dependent since the RPS increased from 60 to 80 with the use of 1-50 µg/shrimp 
(Caipang et al., 2008). 
The recombinant vaccines are meant to be simple, non-infectious, and inexpensive to 
produce in large quantities (Jha et al., 2006; Witteveldt et al., 2004). The rVP28 was found 
to be a common antigen to control WSSV in shrimp (Choi et al., 2011; Mavichak et al., 
2010; van Hulten et al., 2000). In this study, vaccination with the rVP39 temporarily 
delayed mortality compared to rVP28 in both oral and subunit vaccination, suggesting that 
VP39 is potentially suitable as a vaccine against WSSV. Vaccination of P. monodon was 
administered both orally and with intramuscular injection. Even though there are various 
strategies or modes of vaccination such as oral, immersion, intramuscular etc., for farmed 
shrimp and similar cultured aquatic animals, oral administration seems to be the most 
practical approach although there may be some destruction of the proteins in the digestive 
tract which leads to reduced efficiency (Wei and Xu, 2009). Oral administration is also a 
more convenient and inexpensive way of administering potential vaccines to cultured 
aquatic animals (Syed Musthaq and Kwang, 2011). The immersion vaccination method is 
more expensive, and the generated pathogen protection rate is lower than that observed 
with oral vaccination. In this study, vaccination by injection trials showed higher survival 
rate compared to oral vaccination and this result supports the work of Ha et al. (2008). 
Although, vaccination via injection is not feasible in aquaculture farms, it was carried out to 
ensure the application of a consistent amount of protein per shrimp and also to determine 
the potential of protein vaccine. 
In conclusion, oral vaccination of shrimp with rVP39 showed more temporary protective 
efficacy than the more studied rVP28 in both intramuscular and oral vaccination studies. 
Hence, VP39 could potentially be a more potent vaccine than VP28.  
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